There are unique considerations for the design and conduct of clinical trials for rare diseases.

Rare diseases can have genotypic and phenotypic heterogeneity and there may be a lack of clinically meaningful endpoints and biomarkers.

Come hear experts provide the principal investigator, patient advocacy, and regulatory perspectives for how these considerations can be addressed within the context of therapy development for small populations with high unmet needs.